Table 2. Summary of adverse events.

No. participants with AEs, n (%)	Empagliflozin				Placebo (n = 21)
	1 mg (n = 19)	5 mg (n = 21)	10 mg (n = 20)	25 mg (n = 19)
Any AE	6 (31.6)	4 (19.0)	6 (30.0)	7 (36.8)	2 (9.5)
Most frequently reported AEs by preferred term†
Nasopharyngitis	2 (10.5)	1 (4.8)	0 (0.0)	1 (5.3)	0 (0.0)
Constipation	0 (0.0)	1 (4.8)	2 (10.0)	1 (5.3)	1 (4.8)
Upper abdominal pain	0 (0.0)	0 (0.0)	2 (10.0)	0 (0.0)	0 (0.0)
Drug‐related AEs‡	2 (10.5)	0 (0.0)	4 (20.0)	3 (15.8)	1 (4.8)

†Reported by ≥10% of subjects in ≥1 group. ‡Investigator defined. AEs, adverse events.